O7PA.F · NeuBase Therapeutics, Inc

-

Please sign in to comment on O7PA.F

1 Comment

Admin

3 years, 7 months ago

NeuBase Therapeutics, Inc is currently in a long term downtrend where the price is trading 42.5% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

NeuBase Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has increased by 9.7% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 58.4% to $-4M since the same quarter in the previous year.

Based on the above factors, NeuBase Therapeutics, Inc gets an overall score of 2/5.

Sector	Healthcare
Industry	Biotechnology
ISIN	US64132K1025
CurrencyCode	EUR
Exchange	F

Beta	0.89
Dividend Yield	0.0%
Target Price	16.25
PE Ratio	None
Market Cap	5M

ABOUT

NeuBase Therapeutics, Inc

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

O7PA.F · NeuBase Therapeutics, Inc

-

NeuBase Therapeutics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest NeuBase Therapeutics, Inc using a moving average strategy